PEG-coated patch parenchymal closure technique and initial outcomes during minimally invasive partial nephrectomy

Ryan McLarty; Benjamin Beech; Jan K. Rudzinski; Blair St. Martin; Howard Evans
Division of Urology, Department of Surgery, University of Alberta, Edmonton, AB, Canada


Published online August 26, 2021

Corresponding author: Dr. Ryan McLarty, Division of Urology, Department of Surgery, University of Alberta, Edmonton, AB, Canada; mclarty@ualberta.ca

***

Abstract

Introduction: The Hemopatch® is a novel polyethylene glycol-coated (PEG-coated) collagen patch, which acts as a topical hemostatic agent. It has been applied to a variety of surgical techniques. Here, we present our series and technique using a PEG-coated patch for minimally invasive partial nephrectomy (MIPN).

Methods: We conducted a retrospective chart review of all patients undergoing MIPN by a single surgeon at a tertiary Canadian medical center between July and December 2018. We included patients if a PEG-coated patch was used to close the renal parenchymal defect. We also describe in detail our technique for laparoscopic patch deployment.

Results: A total of 17 patients met inclusion criteria, of whom 12 were male. Mean age was 63 years old. Median size of renal mass was 2.85 cm in largest dimension and median RENAL score was 6. Hilar clamping was carried out in 12 (70.9%) cases, with an average warm ischemic time of 16.1 minutes. The remainder of cases were performed off-clamp. Median estimated blood loss was 238 mL and the mean change in hemoglobin on postoperative day 1 compared to preoperatively was 21.2 g/L. The average length of stay was 1.76 days. No patient required blood transfusion or underwent angioembolization or re-operation for bleeding within 90 days. There were no Clavien-Dindo grade 3 or greater complication.

Conclusions: A PEG-coated patch can be used safely and effectively in lieu of traditional two-layer renorrhaphy with acceptable outcomes. Larger, prospective series are required to ascertain its true value and cost-effectiveness.
Introduction

Partial nephrectomy is a first line option for the surgical treatment of small renal masses. Partial nephrectomy rates have been increasing with minimally invasive laparoscopic and robotic techniques being applied to more complex dissections. Partial nephrectomy is associated with a higher risk of post-operative complications compared to radical nephrectomy, especially when considering intraoperative blood loss and post-operative bleeding risk. The need for meticulous hemostasis is often balanced with needing to minimize ischemic time. While there is significant variability in the management of the renal parenchymal defect with respect to hemostasis, the main options include a combination of suture closure and hemostatic agents.

Topical hemostatic agents have become commonplace in minimally invasive partial nephrectomy (MIPN) to reduce bleeding associated with the defect. There has been increasing interest in the use of a new synthetic hemostatic agent, the polyethylene glycol-coated (PEG-coated) collagen patch (Hemoaptch®, Baxter healthcare Corporation) to control intraoperative bleeding. This solid patch can be precisely placed over the area of bleeding direct from the package without preparation unlike other topical agents. Hemostasis is achieved through rapid tissue adherence facilitated by the PEG-coating and stimulated platelet activation and adhesion though its collagen layer. The use of this PEG-coated patch for hemostasis has been described across a number of surgical disciplines for both open and laparoscopic procedures. One area of concern in laparoscopy is unintentionally activating the PEG-layer on adjacent tissue or blood while positioning the patch, which may complicate the ease of use of this patch in laparoscopy compared to open surgery.

Here-in, we describe our initial experience with using a PEG-coated patch in lieu of traditional renorrhaphy during MIPN. Furthermore, we describe our novel laparoscopic deployment technique which facilitates quick patch deployment with minimal unintended tissue contact.

Methods

A retrospective chart review was performed of consecutive patients undergoing robotic assisted MIPN by a single surgeon at the University of Alberta between July and December 2018. This quality assurance assessment met criteria for operational improvement activities and was exempt from local ethics review. During this time frame, a PEG-coated patch was utilized during the renorrhaphy as discussed below in surgical technique. RENAL score was measured as per the method of Kutikov et al. The primary outcome of interest was post-operative angioembolization or surgical reoperation within 90 days. Secondary outcomes included 90-day Clavien-Dindo complications, estimated blood loss, blood transfusion requirements, post-operative hemoglobin change, length of hospital stay and 90-day emergency department visit or hospital admission. Descriptive statistics were provided for the case series.
Surgical technique
All patients underwent robotic assisted MIPN by a single surgeon. Two assistant ports were utilized to ensure both adequate suction and being able to place pressure or pass equipment as needed. The method of hilar clamping was up to the discretion of the surgeon. Mass excision was performed using scissors followed by a single running barbed sutured at the base of the defect anchored with clips. In lieu of a second layer closure aimed at reapproximating the renal cortex, a PEG-coated patch was utilized. Figure 1 depicts preparation and deployment of the PEG-coated patch (Hemopatch®, Baxter Healthcare Corporation). The PEG-coated patch (27mm x 27mm, cost $70 CAD or 45mm x 45mm, cost $185 CAD) was rolled and placed in the cut finger of a surgical glove with the blue dotted side facing outwards (cost data from Baxter Healthcare Corporation, Canada). The patch, protected by the latex glove cover, was introduced by the assistant just beyond the renal parenchymal defect. The patch was then removed from the glove cover, allowing it open PEG-coated side down onto the defect. Gentle continuous pressure was placed over the patch for 2 minutes. If applicable, the hilum was unclamped, and the procedure continued as per usual.

Results
17 patients underwent robotic assisted MIPN during the trial period with all patients receiving a PEG-coated patch renorraphy. Complete follow-up of 90 days was available for all patients. Table 1 describes the characteristics of the sample. The mean age was 63.1 years and 70.6% were male. No patients were on anticoagulation therapy or antiplatelet therapy. Mean tumor size was 2.85 cm and mean numerical RENAL score was 6 (range 4-10). 70.6% of patients had partial nephrectomy performed with hilar clamping compared to no-clamp with a mean warm ischemic time of 16.1 minutes. No patients required addition hemostatic agents or sutures after placement of the PEG-coated patch. The mean estimated blood loss was 238 mL with an mean hemoglobin decline of 21.2 g/L on post-operative day 1. No patient required intraoperative or post-operative blood transfusion, reoperation or angioembolization. There were no complications greater than Clavien-Dindo grade 3 and no patient experienced a 90-day emergency department visit or hospitalization. One patient developed post-operative urinary retention, and another developed a urinary tract infection treated with antibiotics.

Discussion
We demonstrated a novel technique for placement of a PEG-coated patched during MIPN. There is minimal experience with PEG-coated patches during MIPN. Only a single German series has described the feasibility and outcomes of a PEG-coated patch for hemostasis during MIPN. Imkamp et al. first described the successful use of a PEG-coated patch in 2015 for 7 patients undergoing zero-ischemia partial nephrectomy with no complications.11 This series of partial nephrectomy patients, of which 90% were laparoscopic, was subsequently updated in 2020 with
45 patients over a five year period. In this update, they confirmed a PEG-coated patch can be applied to more complex partial nephrectomy patients but reported a 6% rate of intervention for post-operative bleeding.

Furthermore, we found that the use of a PEG-coated patch was feasible and safe with a minimal warm ischemic time. While 2 minutes of pressure is recommended for use of the patch, this time is made up with lack of formal renorrhaphy suturing and was not a concern in our experience. There are similarities and differences between this series and the previously reported series of PEG-coated patch use in partial nephrectomy. Surgical approach, technique with a hemostatic running suture in the defect base, and RENAL scores were similar. We did not use additional hemostatic agents and did not report any blood transfusion or intervention for bleeding. We did have a lower proportion of patients who received an off-clamp technique (55.6% vs. 29.4%). It is difficult to speculate reasons for different outcomes considering our limited number of patients, but we did demonstrate acceptable safety in our limited series with favourable warm ischemic times.

Minimal evidence exists regarding hemostasis during MINP. The Canadian update of surgical procedures (CUSP) urology group recently developed a consensus describing best practices for managing bleeding during renorrhaphy: using a barbed absorbable hemostatic running stich, considering the use of gelatin thrombin agents, placing clips as opposed to knot tying sutures, and early unclamping to identify and ligate bleeding vessels. The use or consideration of PEG-coated patches was not endorsed by the consensus group, likely contributed by the minimal evidence for this technique.

There are several limitations with our series, namely the single center, retrospective design of a limited number of patients. Most tumors had low RENAL scores and it is unknown if similar efficacy would be seen in more complex renal masses. Furthermore, none of the patients were on antiplatelet or anticoagulation and we cannot draw any conclusions in this group. We are also unable to comment on the efficacy of just using a PEG-coated patch without an initial barbed hemostatic stich.

There is currently no comparison between a PEG-coated patch and traditional renorrhaphy techniques with other hemostatic agents. This limits our ability to make conclusions regarding practicality, true efficacy and cost-effectiveness. There are reports of partial nephrectomy technique involving a fibrin sealant patch (TachoSil®). Antonelli et al. found that there was no difference in post-operative complications between patients undergoing partial nephrectomy with either a fibrin sealant patch, Floseal®, or no hemostatic agent at all. Shigeta et al. reported that there was a lower incident of pseudoaneurysm when using a fibrin sealant patch (Tachseal®) compared to standard of care. The role of PEG-coated patches in reducing pseudoaneurysm formation is unknown. A PEG-coated patch may have unique indications for expedited hemostasis during difficult to control bleeding or to expedite prolonged clamp times. While feasible, further prospective studies are required to determine the utility of PEG-coated patches compared to tradition renorrhaphy techniques with other hemostatic agents.
Conclusions
A PEG-coated patch is a feasible and safe option in lieu of traditional renorrhaphy for MINP. We also describe a laparoscopic deployment technique which could be adaptable to any minimally invasive procedure. Further study is required to inform us about the utility of a PEG-coated patch compared to traditional methods of renorrhaphy and other hemostatic agents.
References


Figures and Tables

Fig. 1. (A) Preparation and deployment of a PEG-coated patch into a renal mass defect. The patch is rolled with the adhesive side facing inward and placed into the cut 5th finger of a sterile glove. (B) The assistant deploys the glove finger into the field using a laparoscopic grasper. (C, D) The surgeon can manipulate the hemopatch onto the defect without contact with surrounding tissues and fluids.
<table>
<thead>
<tr>
<th>Patient variable (n=17)</th>
<th>Outcome*</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (years)</td>
<td>63.1 (12.1)</td>
</tr>
<tr>
<td>Male</td>
<td>12 (70.6%)</td>
</tr>
<tr>
<td>Largest tumor dimension (cm)</td>
<td>2.85 (0.87)</td>
</tr>
<tr>
<td>RENAL score **</td>
<td>6 (4-10)</td>
</tr>
<tr>
<td>POD1 hemoglobin drop (g/L)</td>
<td>21.2 (8.8)</td>
</tr>
<tr>
<td>No. with hilar clamp</td>
<td>12 (70.6%)</td>
</tr>
<tr>
<td>Warm ischemic time (min)</td>
<td>16.1 (2.4)</td>
</tr>
<tr>
<td>Estimated blood loss (mL)</td>
<td>238 (115)</td>
</tr>
<tr>
<td>Blood transfusion</td>
<td>0 (0%)</td>
</tr>
<tr>
<td>90-day embolization or reoperation</td>
<td>0 (0%)</td>
</tr>
<tr>
<td>90-day emergency department visit/hospitalization</td>
<td>0 (0%)</td>
</tr>
<tr>
<td>Length of stay (days)</td>
<td>1.8 (0.7)</td>
</tr>
</tbody>
</table>

*Reported as mean (standard deviation) for continuous variables and frequency (percentage) for categorical variables. **Reported as median and range; excluded anterior/posterior/neither designation.